An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits

Vaccine
S Wimer-MackinC Richardson

Abstract

An intranasal vaccine targeting the Bacillus anthracis toxin and vegetative bacterium was tested for the ability to protect immunized rabbits against aerosol B. anthracis spore exposure. Rabbits were vaccinated intranasally with PA-based vaccines formulated as dry powders with or without chitosan (ChiSys, Archimedes Development Limited), a compound that exhibits muco-adhesive properties, or as a liquid. Formulations also contained MPL adjuvant and PA. Some vaccines contained PA conjugated to a 10-mer peptide of the poly-d-glutamic acid capsule of B. anthracis. Rabbits were immunized on days 0 and 28 and aerosol challenged with an average 250LD50 Ames spores on day 85. Serum antibody was measured before and after challenge. Significant anti-PA serum IgG levels were obtained, particularly with use of ChiSys based formulations. PA-Conj induced significant anti-capsule responses, although a formulation containing free capsule peptide did not. All immunized rabbits survived the challenge, but differences in morbidity, as evidenced by anorexia, between vaccine groups were observed. Only rabbits immunized with PA+PA-Conj appeared normal throughout the post-challenge observation period (14 days), while all that received PA with the fre...Continue Reading

References

May 1, 1993·The Journal of Infectious Diseases·A M FriedlanderP Mikesell
Sep 4, 1999·Journal of Applied Microbiology·A M Friedlander
Apr 9, 2001·Infection and Immunity·S ReuvenyB Velan
Aug 24, 2001·The Journal of Pharmacy and Pharmacology·A K Singla, M Chawla
Dec 19, 2001·Emerging Infectious Diseases·J A JerniganUNKNOWN Anthrax Bioterrorism Investigation Team
Aug 22, 2003·Oral Microbiology and Immunology·F LiN K Childers
Sep 10, 2003·Proceedings of the National Academy of Sciences of the United States of America·Gi-Eun RhieJulia Y Wang
Sep 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·G HermansonP Hobart
Nov 3, 2004·Vaccine·Donald J ChabotArthur M Friedlander
Dec 21, 2004·The Journal of Infectious Diseases·John A MiksztaNoel G Harvey
Nov 30, 2005·Journal of Pharmaceutical Sciences·Ge JiangVincent J Sullivan

❮ Previous
Next ❯

Citations

Jul 31, 2007·Future Microbiology·Karla D Passalacqua, Nicholas H Bergman
Nov 21, 2007·Journal of Liposome Research·Liliam Becherán MarónMaria Helena Bueno da Costa
Apr 6, 2007·Expert Review of Vaccines·Dongmei Lu, Anthony J Hickey
Jun 23, 2009·Expert Review of Vaccines·H Ciğdem ArcaSevda Senel
Mar 7, 2008·Expert Opinion on Emerging Drugs·Pritish K Tosh, Gregory A Poland
Nov 5, 2010·Journal of Drug Targeting·Inderjit Jabbal-Gill
Jun 20, 2012·Expert Opinion on Drug Delivery·Inderjit Jabbal-GillAlan Smith
Oct 20, 2009·Vaccine·Arthur M Friedlander, Stephen F Little
Sep 5, 2009·Molecular Aspects of Medicine·Robert J CybulskiAlison D O'Brien
Nov 23, 2012·Influenza and Other Respiratory Viruses·Signe C SvindlandRebecca J Cox
Nov 12, 2010·Tuberculosis·David A Hokey, Amit Misra
Dec 12, 2007·Journal of Leukocyte Biology·Alan S CrossMyron M Levine
Feb 24, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Wolfgang KastenmullerIngo Drexler
Jan 28, 2010·Journal of Medicinal Chemistry·Dimitrios G Bouzianas
Oct 20, 2018·Journal of Controlled Release : Official Journal of the Controlled Release Society·Sachin G ThakkarZhengrong Cui
Jun 25, 2015·Microbiology Spectrum·Susan WelkosChristopher Cote

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.